Previous close | 17.44 |
Open | 17.55 |
Bid | 17.40 x 1800 |
Ask | 17.47 x 2900 |
Day's range | 17.06 - 17.55 |
52-week range | 12.43 - 20.00 |
Volume | 3,246,189 |
Avg. volume | 3,842,667 |
Market cap | 54.874B |
Beta (5Y monthly) | 1.11 |
PE ratio (TTM) | 21.53 |
EPS (TTM) | 0.81 |
Earnings date | N/A |
Forward dividend & yield | 0.85 (4.86%) |
Ex-dividend date | 29 Sep 2020 |
1y target est | 22.61 |
Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.
Merck (MRK) is stepping up to help Johnson & Johnson (JNJ) produce its COVID-19 vaccine, which was authorized last weekend.
Children's National Hospital and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program, which will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases.